M
Mei-Lin Ah-See
Researcher at Northwood University
Publications - 21
Citations - 869
Mei-Lin Ah-See is an academic researcher from Northwood University. The author has contributed to research in topics: Breast cancer & Dynamic contrast-enhanced MRI. The author has an hindex of 11, co-authored 21 publications receiving 765 citations. Previous affiliations of Mei-Lin Ah-See include Mount Vernon Hospital & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Mei-Lin Ah-See,Andreas Makris,N. Jane Taylor,Mark Harrison,P I Richman,RJ Burcombe,J. James Stirling,James A. d’Arcy,David J. Collins,M. Pittam,D Ravichandran,Anwar R. Padhani +11 more
TL;DR: Changes in breast tumor microvessel functionality as depicted by DCE-MRI early on after starting anthracycline-based neoadjuvant chemotherapy can predict final clinical and pathologic response.
Journal ArticleDOI
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Helena M. Earl,Helena M. Earl,Helena M. Earl,Louise Hiller,Anne-Laure Vallier,Shrushma Loi,Karen McAdam,Karen McAdam,Luke Hughes-Davies,Adrian Harnett,Mei-Lin Ah-See,Richard Simcock,Daniel Rea,Sanjay Raj,Pamela Woodings,Mark Harries,Donna L. Howe,Kerry Raynes,Helen B Higgins,Maggie Wilcox,Chris Plummer,Chris Plummer,Janine Mansi,Ioannis Gounaris,Betania Mahler Araujo,Elena Provenzano,Elena Provenzano,Anita Chhabra,Jean Abraham,Jean Abraham,Jean Abraham,Carlos Caldas,Peter Hall,Christopher McCabe,Claire Hulme,Claire Hulme,David Miles,Andrew M Wardley,David Cameron,Janet A. Dunn,Roshan Agarwal,Hafiz Algurafi,Rozenn Allerton,Caroline Archer,Anne C Armstrong,Catherine Bale,Lisa H Barraclough,Urmila Barthakur,Carolyn Bedi,Kim Benstead,D. Bloomfield,Rebecca Bowen,Chris Bradley,Jane Brown,Mohammad Butt,Mark Churn,Susan Cleator,Joanne Cliff,Perric Crellin,Margaret Daly,Shiroma De Silva-Minor,A.S. Dhadda,O.S. Din,Sue Down,H. M. Earl,David J. Eaton,Andrew Eichholz,Daniel Epurescu,Chee Goh,Andrew D. Goodman,Robert Grieve,Maher Hadaki,Catherine Harper-Wynne,Larry Hayward,A. Humphreys,Helen Innes,Mariam Jafri,Apurna Jegannathen,Muireann Kelleher,Hartmut Kristeleit,Daniela Lee,Susan Lupton,Carol MacGregor,Zafar Malik,Jennifer Marshall,Trevor McGolick,Rakesh Mehra,Natasha Mithal,Charlotte Moss,Aian Moss,Mukesh Mukesh,Anthony Neal,Daniel Nelmes,Helen Neville-Webbe,Jacqueline Newby,S O'Reilly,Peter Ostler,Mojca Persic,Laura Pettit,Fharat A. Raja,Catherine Reed,Anne Rigg,Helen Roe,Nihal Shah,Peter Simmonds,Eliot Sims,Sarah Smith,Nicola Storey,Wendy Taylor,Narottam Thanvi,Karen Tipples,Jayant S. Vaidya,Mohini Varughese,Anup Vinayan,Nawaz Walji,Simon Waters,Kathryn Wright,Sundus Yahya +117 more
TL;DR: 6-month trastuzumab treatment is shown to be non-inferior to 12-month treatment in patients with HER2-positive early breast cancer, with less cardiotoxicity and fewer severe adverse events, which support consideration of reduced duration trastzumab for women at similar risk of recurrence as to those included in the trial.
Journal ArticleDOI
Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy
Sonia P. Li,Andreas Makris,Mark Beresford,N. Jane Taylor,Mei-Lin Ah-See,J. James Stirling,James A. d’Arcy,David J. Collins,Robert Kozarski,Anwar R. Padhani +9 more
TL;DR: Dynamic contrast-enhanced MR imaging parameters, in conjunction with traditional prognostic factors, have the potential to be prognostic biomarkers for disease-free and overall survival in primary breast cancer.
Journal ArticleDOI
Vascular characterisation of triple negative breast carcinomas using dynamic MRI
Sonia P. Li,Anwar R. Padhani,N. Jane Taylor,Mark Beresford,Mei-Lin Ah-See,J. James Stirling,James A. d’Arcy,David J. Collins,Andreas Makris +8 more
TL;DR: TNBC possess characteristic features on imaging, with lower extracellular space (higher cell density) and higher contrast agent wash-out rate (higher vascular permeability) suggesting a distinctive phenotype detectable by MRI.
Journal ArticleDOI
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.
Helena M. Earl,Louise Hiller,Anne-Laure Vallier,Shrushma Loi,Donna L. Howe,Helen B Higgins,Karen McAdam,Luke Hughes-Davies,Adrian Harnett,Mei-Lin Ah-See,Richard Simcock,Daniel Rea,Janine Mansi,Jean Abraham,Carlos Caldas,Claire Hulme,David Miles,Andrew M Wardley,David Cameron,Janet A. Dunn +19 more
TL;DR: PERSEPHONE is a randomised phase 3 non-inferiority trial comparing 6 to 12m trastuzumab, the largest reduced-duration non-InferIORity trial internationally.